Collaborating with R-Pharm to deliver GenQual’s predictive diagnostics for novel anti-IL-6 antibody for autoimmune diseases

GenQual – R-Pharm Press Release: May 24, 2016, San Francisco, CA USA; Moscow, Russia; Seattle, WA, USA;  R-Pharm and GenQual are pleased to announce a new collaboration focused on the development of novel predictive diagnostic tools in the area of Rheumatoid Arthritis and Autoimmune diseases. The GenQual proprietary real-time PCR platform, when applied to the genes that are involved in the manifestation of several autoimmune diseases, allows us to detect and assess single nucleotide polymorphisms. Here, allelic determination is used as potential predictor ... Read more

GenQual announces availability of Series AA shares to qualified investors

For qualified investors only: GenQual announces availability of Series AA shares in funding extension to first round.  This funding will allow GenQual to continue to pursue proof-of-principle testing for its companion diagnostic approach for IL-6 mAb  and other JAK/STAT inhibitors for autoimmune diseases and oncology indications. GenQual companion diagnostic candidates aim to prospectively identify responders for clinical-stage therapeutics to improve drug trial response rates and improve chances for drug approval. GenQual Founder and CEO Jonathan Mirich said, “We have conservatively managed our Series AA funding and are pleased ... Read more

Dr. Ralph Paul, Ph. D. joins GenQual as Technical Advisor and Co-Investigator

GenQual is pleased to announce that Dr. Ralph Paul, Ph. D. has joined the company to help further our companion diagnostic candidates as Technical Advisor and Co-Investigator. Dr. Paul has comprehensive experience in the Biotech industry in a number of capacities–bench level scientist, Sr. Scientist, Program Lead and Director, grant and RFP preparation, business development, patent filings, licensing, and drug development. He was the Sr. Product Manager at Cerep and the Director of Technology Assessment and Discovery while with Targeted Genetics Corp. ... Read more

Dr. Yury Colton, Ph. D., J.D. joins GenQual as Chief Operating Officer and General Counsel

GenQual is pleased to announce that Dr. Yury Colton has joined the team as COO and General Counsel. Dr. Colton carries a wealth of technical and legal experience in broad areas of the life science industry, including molecular diagnostics. Prior to joining GenQual, Yury worked as a patent attorney managing domestic and international patents for large and small companies and research institutions with Stoel Rives, LLP. He serves as a Trustee with the National Multiple Sclerosis Society. Dr. Colton's scientific research included ... Read more

Dr. Luman Wing, Ph.D. joins GenQual Board of Advisors

GenQual is pleased to announce that Dr. Luman Wing, Ph.D. has joined the Board of Advisors.  Dr. Wing is currently Director, Executive Consultant, Scientific Consulting at Beckloff Associates, a wholly-owned subsidiary of Cardinal Health.  He has over 18 years experience in management of therapeutic development programs, toxicology, pharmacokinetic and bioanalytical study design.  He has extensive experience interacting with FDA via Information Packages, Investigational New Drug (IND) Applications, and New Drug Applications (NDA).  Dr. Wing received his Ph.D. in Biochemistry at the ... Read more

Howard Mendelsohn, CMA joins GenQual Board of Advisors

GenQual is pleased that Howard Mendelsohn has joined the Board of Advisors. Mr. Mendelsohn was previously was a consulting advisor with CFO Selections, and provided financial models and advice to GenQual pre-Series AA. Howard Mendelsohn is currently Chief Financial and Operating Officer of Sustainable Fisheries Partnership. He brings over 20 years of industry experience in a variety of senior financial and operating roles. Previously he served in senior management of Expedia, Inc. where he oversaw the company's worldwide financial operations. He ... Read more

GenQual announces initial closing of its Series AA preferred equity funding round

GenQual is pleased to announce initial closing of its first preferred equity round. Financial terms were not disclosed.  This inaugural funding round allows GenQual to pursue proof-of-principle testing for its companion diagnostic approach for IL-6 mAb  and other JAK/STAT inhibitors for autoimmune diseases and oncology indications. GenQual aims to prospectively identify responders for clinical-stage therapeutics to improve drug trial response rates and improve chances for drug approval.  The round remains open for further funding.   GenQual Founder and CEO Jonathan Mirich said, “This ... Read more

Dr. David M. Jackson, Ph.D. joins GenQual Board of Advisors

GenQual is pleased to announce that Dr. David M. Jackson has joined the Board of Advisors.  Dr. Jackson is currently Senior Director, Companion Diagnostic Partnerships at QIAGEN, Inc. (formerly DxS).  Dr. Jackson has extensive experience in companion diagnostic partnerships, business development,, and regulatory and commercialization strategy.  He was previously VP Business Development & Licensing at DxS Ltd., which commercialized the therascreen® KRAS mutation assay (EU CE-IVD mark) as a companion diagnostic for colorectal carcinoma therapies Vectibix® and Erbitux®.  He received his ... Read more

GenQual at WBBA Life Sciences Innovations Northwest

GenQual will be attending WBBA LSINW conference March 2-3 at the Washington State Convention Center in Seattle.  We are reviewing meeting requests via Biopartnering.com, or get in touch with us at info@genqual.com. Read more

Dr. Philip Mease, MD joins GenQual Board of Advisors

GenQual announced today that Dr. Philip Mease has joined the Board of Advisors.  Philip Mease, MD, is Clinical Professor at the University of Washington School of Medicine in Seattle, Director of the Rheumatology Clinical Research Division of Swedish Medical Center, and his clinical practice is based at Seattle Rheumatology Associates. He conducts clinical trials of emerging therapies for rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, osteoarthritis and lupus. He conducts research in disease state metrics and is ... Read more